

ACADIA PHARMACEUTICALS INC  
Form 8-K  
September 12, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  
September 6, 2013

Commission File Number:  
000-50768

ACADIA Pharmaceuticals  
Inc.

(Exact name of small business issuer as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation or  
organization)

061376651  
(IRS Employer Identification No.)

11085 Torreyana Road #100, San Diego,  
California 92121

(Address of principal executive offices)

858-558-2871

(Registrant's Telephone number)

3911 Sorrento Valley Boulevard, San  
Diego, CA 92121

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.

On September 6, 2013, the Board of Directors of ACADIA Pharmaceuticals Inc. (the "Company") approved an amendment to the Amended and Restated Bylaws of the Company.

A new Section 47 was added to the bylaws to specify the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain actions involving the Company. The Amended and Restated Bylaws, which are included as an exhibit to this report, were effective as of September 6, 2013.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

Date: September 12, 2013

By: /s/ Glenn F. Baity

Name: Glenn F. Baity

Title: Vice President & General Counsel

Exhibit Index

Exhibit No.	Description
EX-3.1	Amended and Restated Bylaws of ACADIA Pharmaceuticals Inc.